First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial

被引：0
|
作者：
Sobrero, A.
Ackland, S.
Perez Carrion, R.
Chiara, S.
Clarke, S.
Garcia Giron, C.
Langer, B.
Zurlo, A.
Young, S.
机构：
[1] NE Ontario Reg Canc Ctr, Sudbury, ON, Canada
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[3] Hosp Gen Yage, Dept Med Oncol, Burgos, Spain
[4] Sydney Canc Ctr, Dept Oncol, Concord, Australia
[5] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[6] MD Anderson Int Espana, Ctr Oncol, Madrid, Spain
[7] Newcastle Mat Misericordiae Hosp, Dept Med Oncol, Waratah, Australia
[8] Clin Univ Convenz UO Oncol Med, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC
    Sobrero, Alberto
    Ackland, Stephen
    Carrion, Ramon Perez
    Chiarra, Silvana
    Clarke, Stephen
    Giron, Carlos Garcia
    Langer, Bernd
    Andre, Niko
    Young, Scott
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [2] A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC:: AVIRI
    Sobrero, A.
    Young, S.
    Balcewicz, M.
    Chiara, S.
    Perez-Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII18 - VII19
  • [3] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [5] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [6] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [7] Randomised comparison of 5-FU/folinic acid plus irinotecan (FOLFIRI) and irinotecan plus oxaliplatin (IROX) in first-line therapy of metastatic colorectal cancer (CRC):: the fire-trial
    von Weikersthal, L. Fischer
    Schalhorn, A.
    Quietzsch, D.
    Maubach, P. A.
    Schlimok, G.
    Lambertz, H.
    Weigang-Koehler, K.
    Schultz, M.
    Schlag, R.
    Grundeis, M.
    Heinemann, V.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 167 - 167
  • [8] Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial.
    Schalhorn, A
    Ludwig, FW
    Quietzsch, D
    Maubach, PA
    Schlimok, G
    Lambertz, H
    Weigang-Koehler, K
    Schulze, M
    Schlag, R
    Grundeis, M
    Heinemann, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [9] MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN
    Holmberg, C.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    Gyldmark, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [10] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345